A remote, patient-centred, randomized trial demonstrated that canagliflozin, an SGLT2 inhibitor, significantly decreased hospitalization rates among patients with diabetes and heart failure by alleviating symptom burden, thereby enhancing patients' functional status and overall quality of life [35]. The gene discussed is SLC5A2; the disease is heart failure.